Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder

  title={Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder},
  author={Chi-Un Pae and Hyun Kook Lim and Neena Ajwani and Chul Lee and Ashwin A. Patkar},
  journal={Expert Review of Neurotherapeutics},
  pages={603 - 615}
  • C. Pae, H. Lim, A. Patkar
  • Published 1 June 2007
  • Psychology, Medicine
  • Expert Review of Neurotherapeutics
There is abundant evidence for abnormalities of both norepinephrine and serotonin neurotransmitter systems in post-traumatic stress disorder (PTSD). Venlafaxine extended-release formulation (venlafaxine XR) is a serotonin and norepinephrine re-uptake inhibitor with antidepressant and anxiolytic properties relevant to the pathophysiology of PTSD. Venlafaxine XR is currently approved for the treatment of panic disorder, generalized anxiety disorder and social anxiety disorder, as well as major… 
Desvenlafaxine Succinate: A Newer Antidepressant for the Treatment of Depression and Somatic Symptoms
Current evidence indicates that DVS has proven efficacy, acceptable safety and tolerability profiles, convenient dosing, and minimal impact on the cytochrome P450 enzyme system, which is a potential advantage over other selective serotonin noradrenaline reuptake inhibitors.
Noradrenergic vs Serotonergic Antidepressant with or without Naltrexone for Veterans with PTSD and Comorbid Alcohol Dependence
It is suggested that norepinephrine uptake inhibitors may present clinical advantages when treating male veterans with PTSD and AD, however, naltrexone did not show evidence of efficacy in this population.
Treatment of PTSD and Chronic Daily Headache
Treatment studies on individuals with CDH and comorbid PTSD are limited and multiple therapeutic agents or modes of interventions typically are necessary, such that comprehensive treatment simultaneously utilizes approaches with established efficacy for each individual condition.
Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double‐blind, placebo‐controlled study
Although there have been important advances in the treatment of posttraumatic stress disorder (PTSD), many patients fail to respond to first‐line pharmacotherapy. Limited evidence suggests that
Complex Trauma in Adolescents and Adults: Effects and Treatment.


Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.
CONTEXT No large-scale posttraumatic stress disorder drug trials have been conducted to evaluate treatment effects beyond 12 weeks outside of those with selective serotonin reuptake inhibitors.
Venlafaxine: a 2003 update.
Venlafaxine Extended Release in Posttraumatic Stress Disorder: A Sertraline- and Placebo-controlled Study
The venlafaxine ER group had significantly better Davidson Trauma Scale total and cluster scores than placebo and both treatments were generally well tolerated.
Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment.
The acute efficacy of sertraline is sustained in the vast majority of patients, and at least half of nonresponders to acute treatment will eventually respond to continued treatment.
Sertraline, Paroxetine, and Venlafaxine in Refugee Posttraumatic Stress Disorder with Depression Symptoms
Three new antidepressants were used in treating posttraumatic stress disorder (PTSD) and symptoms of depression in Bosnian refugees, and all 32 refugees remained PTSD positive at the diagnostic level at the 6-week follow-up.
Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial.
The data suggest that sertraline is a safe, well-tolerated, and effective treatment for PTSD.
Characterizing the effects of sertraline in post-traumatic stress disorder
Effects of sertraline are more apparent on the psychological rather than somatic symptoms of PTSD, with an early modulation of anger and, perhaps, other affects, preceding improvement in other symptoms.
Paroxetine: current status in psychiatry
  • C. Pae, A. Patkar
  • Psychology, Medicine
    Expert review of neurotherapeutics
  • 2007
The efficacy and tolerability data for paroxetine appears to be comparable with other SSRIs in the treatment of major depression, and it is approved for use in a wider variety of anxiety disorders than any other antidepressant.
Noradrenergic and serotonergic function in posttraumatic stress disorder.
Data suggest the presence of 2 neurobiological subgroups of patients with PTSD, one with a sensitized noradrenergic system, and the other with a Sensitized serotonergic system.